Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study
B Tombal, M Borre, P Rathenborg, P Werbrouck… - The lancet …, 2014 - thelancet.com
Background The androgen receptor inhibitor enzalutamide is approved for the treatment of
metastatic castration-resistant prostate cancer that has progressed on docetaxel. Our aim …
metastatic castration-resistant prostate cancer that has progressed on docetaxel. Our aim …
[HTML][HTML] Long-term efficacy and safety of enzalutamide monotherapy in hormone-naïve prostate cancer: 1-and 2-year open-label follow-up results
B Tombal, M Borre, P Rathenborg, P Werbrouck… - European urology, 2015 - Elsevier
Background Enzalutamide is an androgen receptor inhibitor with a demonstrated overall
survival benefit in metastatic castration-resistant prostate cancer. A phase 2 study of …
survival benefit in metastatic castration-resistant prostate cancer. A phase 2 study of …
ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer
AJ Armstrong, RZ Szmulewitz, DP Petrylak… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated
significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We …
significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We …
Enzalutamide with standard first-line therapy in metastatic prostate cancer
Background Enzalutamide, an androgen-receptor inhibitor, has been associated with
improved overall survival in men with castration-resistant prostate cancer. It is not known …
improved overall survival in men with castration-resistant prostate cancer. It is not known …
Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC).
MR Smith, M Borre, P Rathenborg, P Werbrouck… - 2013 - ascopubs.org
5001 Background: In locally-advanced prostate cancer, the antiandrogen bicalutamide (Bic)
is used to maintain quality of life relative to castration therapy (LHRHa), but efficacy as a …
is used to maintain quality of life relative to castration therapy (LHRHa), but efficacy as a …
Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer
M Hussain, K Fizazi, F Saad… - … England Journal of …, 2018 - Mass Medical Soc
Background Men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising
prostate-specific antigen (PSA) level are at high risk for metastasis. We hypothesized that …
prostate-specific antigen (PSA) level are at high risk for metastasis. We hypothesized that …
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
Background Enzalutamide is an oral androgen-receptor inhibitor that has been shown to
improve survival in two placebo-controlled phase 3 trials, and is approved for patients with …
improve survival in two placebo-controlled phase 3 trials, and is approved for patients with …
Long-term antitumor activity and safety of enzalutamide monotherapy in hormone naïve prostate cancer: 3-year open label followup results
B Tombal, M Borre, P Rathenborg, P Werbrouck… - The Journal of …, 2018 - Elsevier
Purpose A phase 2 study of enzalutamide monotherapy in patients with hormone naïve
prostate cancer demonstrated high prostate specific antigen response rates at 25 weeks, 1 …
prostate cancer demonstrated high prostate specific antigen response rates at 25 weeks, 1 …
A European, prospective, observational study of enzalutamide in patients with metastatic castration‐resistant prostate cancer: PREMISE
H Payne, A Robinson, B Rappe… - … Journal of Cancer, 2022 - Wiley Online Library
In randomized clinical trials, the androgen‐receptor inhibitor enzalutamide has
demonstrated efficacy and safety in metastatic castration‐resistant prostate cancer …
demonstrated efficacy and safety in metastatic castration‐resistant prostate cancer …
The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients
CS Kim, A Theeuwes, DD Kwon… - … and clinical urology, 2016 - synapse.koreamed.org
Purpose This post hoc analysis evaluated treatment effects, safety, and pharmacokinetics of
enzalutamide in Korean patients in the phase 3, double-blind, placebo-controlled PREVAIL …
enzalutamide in Korean patients in the phase 3, double-blind, placebo-controlled PREVAIL …
相关搜索
- hormone naïve prostate cancer
- enzalutamide monotherapy prostate cancer
- open label prostate cancer
- primary analysis prostate cancer
- enzalutamide in men prostate cancer
- placebo in men prostate cancer
- metastatic prostate cancer
- efficacy and safety prostate cancer
- safety of enzalutamide prostate cancer
- enzalutamide in patients prostate cancer
- enzalutamide or placebo prostate cancer
- enzalutamide and survival prostate cancer
- men with nonmetastatic prostate cancer
- korean patients prostate cancer
- antitumor activity prostate cancer
- survival in nonmetastatic prostate cancer